Build status - In Progress

18F-FluorThanatrace positron emission tomography (PET/CT) in Patients with Metastatic Prostate Cancer

18F-FluorThanatrace positron emission tomography (PET/CT) in Patients with Metastatic Prostate Cancer
Recruiting
18 years - 99 years
Male
Phase 1
30 participants needed
1 Location

Brief description of study

The research study is being conducted to test how a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) can be used to take computerized pictures of places in the body where prostate cancer has spread (metastasized). The pictures will be taken before, and optionally after treatment. 18F-FTT is a drug used with an imaging test called Positron Emission Tomography/Computed Tomography (PET/CT).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Metastatic Prostate Cancer
  • Age: 18 years - 99 years
  • Gender: Male

Males. over age 18, diagnoses with Metastatic Prostate Cancer

Updated on 04 Aug 2024. Study ID: 849671

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center